Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study

American Heart Journal

Volumn 146, Issue 4, 2003, Pages 628-634

  Ferguson, James J ^a   Antman, Elliott M ^b   Bates, Eric R ^c   Cohen, Marc ^d   Every, Nathan R ^e   Harrington, Robert A ^f   Pepine, Carl J ^g   Theroux, Pierre ^h  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0142088816     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00165-0     Document Type: Article

References (26)

1. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
2. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.
3. Antman EM, Cohen M, McCabe C, et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002;23:308-14.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
5. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events). J Am Coll Cardiol 2000;36:693-8.
6. O'Brien BJ, Willan A, Blackhouse G, et al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000;139:423-9.
7. Detournay B, Huet X, Fagnani F, et al. Economic evaluation of enoxaparin sodium versus heparin in unstable angina: a French sub-study of the ESSENCE trial. Pharmacoeconomics 2000;18:83-9.
8. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events). Circulation 1998;97:1702-7.
9. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first." J Invasive Cardiol 2000;12(Suppl A):1-5A.
10. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaporin in acute coronary syndromes. Int J Cardiol 1999;71:273-81.
11. Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. J Invasive Cardiol 2000;12(Suppl E):E5-9; E25-8.
12. Cohen M, Theroux P, Frey M, et al. Antithrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Amer Heart J 2002;144:470-7.
13. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8.
14. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
15. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
17. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
18. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
19. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
20. Hirsh J, Workentin TE, Raschke R, et al. Heparin and low-molecular- weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(5 Suppl):489-510S.
21. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular- weight heparin or unfractionated heparin [see comments]. N Engl J Med 1995;332:1330-5.
22. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. TACTICS-TIMI-18 Investigators. N Engl J Med 2001;344:1879-87.
23. Bhatt DL, Lincoff AM, the CRUISE Investigators. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: the results of the CRUISE trial. Circulation 2001;104(17 Suppl II):II-384-5.
24. Goodman SG. The INTERACT study. Paper presented at: 51st Scientific Session of the American College of Cardiology; March 17-20, 2002; Atlanta, Ga.
25. Michalis LK, Papamichail N, Katsouras CS, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study). J Am Coll Cardiol 2001;37(2 Suppl A):365A.
26. Montalescot G, Cohen A, Slama M, et al. A randomized comparison of enoxaparin, dalteparin and unfractionated heparin in unstable angina evaluating markers of cell activation (the ARMADA study). Circulation 2001;104:II-549.